In a report released yesterday, Kyle Mikson CFA from Canaccord Genuity maintained a Buy rating on Exact Sciences (EXAS – Research Report), with a price target of $75.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Kyle Mikson CFA’s rating is based on a combination of factors that suggest Exact Sciences is poised for long-term growth. Despite the modest core revenue growth, the company reported a solid year-over-year revenue increase of 14% in their screening division, aligning with expectations. This solid performance, along with the company’s guidance for 2025 revenue being in line with consensus, supports the Buy rating.
Exact Sciences is expected to benefit from several tailwinds and product launches, particularly the Cologuard Plus, which should positively impact revenue growth in the latter half of 2025. The company’s management remains confident in achieving its long-term financial targets, expecting a compound annual growth rate of over 15% in total revenue from 2022 to 2027. These factors, coupled with the company’s strategic plans and market position, underpin the optimistic outlook for Exact Sciences’ stock.
Mikson CFA covers the Healthcare sector, focusing on stocks such as Natera, Guardant Health, and Castle Biosciences. According to TipRanks, Mikson CFA has an average return of -10.4% and a 30.65% success rate on recommended stocks.
In another report released today, Piper Sandler also maintained a Buy rating on the stock with a $75.00 price target.